Adherium Ltd. · ASX:ADR
Adherium — Investor Presentation (April 2021)
10 slides from Adherium's investor presentation, April 2021
Slide 1: Establishing leadership in the rapidly accelerating respiratory remote digital monitoring environment
Establishing leadership in the rapidly accelerating respiratory remote digital monitoring environment APRIL 2021
Slide 2: Establishing leadership in respiratory remote digital monitoring
adherium Establishing leadership in the rapidly accelerating respiratory remote digital monitoring environment Rapid evolution of telehealth & remote digital monitoring, accelerated by COVID and new reimbursement programs Well placed with strategy development beyond adherence alone, toward multi-sen
Slide 3: Opportunity: telehealth and remote digital management transformed
opportunity Telehealth & remote digital management of patients transformed in last 24 months due to introduction of reimbursement codes & impact of COVID pandemic COVID has changed expectations Reimbursement availability now on care delivery a catalyst for adoption Estimates of pre-pandemic awarenes
Slide 4: Strategy evolution
strategy Opportunity NOW to transform Adherium to lead commercially valuable integrated management solutions respiratory digital management ecosystem evolution Sensors Portal Adherence Revenue generation Healthcare providers & payers Adherence & Technique Partner Summatix / Planet Innovation Integra
Slide 5: Positive progression with existing partners and product portfolio
strategy Positive progression with existing partners & product portfolio Existing Partners Current Portfolio Sensors Physiologically enabled sensor development progressing well (plan Phase 1 training completed increases asthma/COPD device market coverage from 56% to 80% by US Pilot Program of evalua
Slide 6: Rapid acceleration in telehealth and digital monitoring increases partnering opportunities
Rapid acceleration in telehealth & digital monitoring reflected in increased partnering strategy opportunities strengthening revenue stream potential with >10 ongoing commercial partnering engagements currently progressing at C suite level Partner Type Disease/Population Management Partners CDMO’s P
Slide 7: Ecosystem evolution enhances overall product proposition
Ecosystem evolution enhances overall product proposition to end clinical providers & payors strategy with multiple longitudinal data points, leverages portal platform, & extends revenue stream potential for individual & combination of assets beyond adherence alone Ecosystem Initial ecosystem of Adhe
Slide 8: Business Evolution Road Map
strategy Business Evolution Road Map 1 CY Q3 2020 – Q2 2021 Initial partner model establishment/proof of concept 2 CY Q2 2021 – Q4 2021 Partner scale-up in US with revenue traction 3 CY 2022 Full expansion & platform leverage in US & ex-US Validate channel partners Scale-up of HGE & Monaghan; initia
Slide 9: Disclaimer and forward looking statement
Disclaimer and forward looking statement The material contained herein is of a general nature & has only commercial products & (vi) other risks & uncertainties related to been prepared as a presentation aid. This presentation does NOT the Company’s prospects, assets / products & business strategy. c
Slide 10: APRIL 2021
APRIL 2021